Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis (Q38039763)

27 August 2017

title

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

27 August 2017

main subject

0 references

Thomas Dick

9

0 references

Scott G. Franzblau

object named as

Scott G Franzblau

1

0 references

Veronique Dartois

10

object named as

Veronique Dartois

1 reference

27 August 2017

6

Ian M Orme

1 reference

27 August 2017

Iñigo Angulo-Barturen

8

object named as

Iñigo Angulo-Barturen

1 reference

27 August 2017

5

Eric Nuermberger

1 reference

27 August 2017

Mary Ann DeGroote

2

1 reference

27 August 2017

Sang Hyun Cho

3

1 reference

27 August 2017

Koen Andries

4

1 reference

27 August 2017

Khisimuzi Mdluli

7

1 reference

27 August 2017

Anne J Lenaerts

11

1 reference

27 August 2017

publication date

30 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

92

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

453-488

1 reference

Drugs in development for tuberculosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Tuberculosis drug development: progress, challenges, and the road ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Current development and future prospects in chemotherapy of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Drugs for bad bugs: confronting the challenges of antibacterial discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Using animal models to develop new treatments for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

FACTORS AFFECTING THE GROWTH OF TUBERCLE BACILLI IN LIQUID MEDIA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

THE EFFECT OF SALICYLATE ON THE OXYGEN UPTAKE OF THE TUBERCLE BACILLUS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The tuberculostatic action of vitamin D2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Quantitative measurement of growth of Mycobacterium tuberculosis; effect of streptomycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

THE BINDING OF FATTY ACIDS BY SERUM ALBUMIN, A PROTECTIVE GROWTH FACTOR IN BACTERIOLOGICAL MEDIA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Some further studies on tuberculostatic compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

On the effect of isomers of para-aminosalicylic acid and related substances on the tuberculostatic effect of PAS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

On the use of an egg agar medium in the determination of the resistance of Mycobacterium tuberculosis to streptomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Investigation into the tuberculostatic activity of some derivatives of p. amino-benzoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Investigation into the tuberculostatic activity of some aromatic hydroxy compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The tuberculostatic action of terramycin in vitro and in the experimental animal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Effects of antimicrobial agents on the tubercle bacillus and on experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The tuberculostatic activity of some thiosemicarbazones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Tuberculostatic effect of furacin in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

An approach to a correlation between in vivo and in vitro activities of antitubercular compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The tuberculostatic properties of the unsaponifiable fraction of cod liver oil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Tryptophane as a tuberculostatic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Tuberculostatic substances extracted from normal rat spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

A whole blood bactericidal assay for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Animal models of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Preclinical testing of new drugs for tuberculosis: current challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Experimental evaluation of antibacterial agents in tuberculosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The use of mice in experimental chemotherapy of tuberculosis; the histopathologic assay of chemotherapeutic action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The use of mice in experimental chemotherapy of tuberculosis; pathology and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The use of mice in experimental chemotherapy of tuberculosis; rationale and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The effect of streptomycin on well-established experimental tuberculosis of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Bacteriology of tuberculosis: laboratory methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The antitubercular activity of 3-acetylthiopropylene sulphide and 3-(2-furoylthio) propylene sulphide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

INFECTION OF MICE WITH MAMMALIAN TUBERCLE BACILLI GROWN IN TWEEN-ALBUMIN LIQUID MEDIUM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The toxic and antituberculous effects of two thiosemicarbazones and streptomycin in dogs, monkeys, and guineapigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Studies on the antituberculous activity of ethambutol in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Designation of Strain H37Rv as the Neotype of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

BIOLOGICAL STUDIES OF THE TUBERCLE BACILLUS : III. DISSOCIATION AND PATHOGENICITY OF THE R AND S VARIANTS OF THE HUMAN TUBERCLE BACILLUS (H(37)).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Centenary of the discovery of the tubercle bacillus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Robert Koch: centenary of the discovery of the tubercle bacillus, 1882

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Streptomycin; a valuable anti-tuberculosis agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Chemotherapy of tuberculosis; research during the past 100 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Reversal of tuberculin reaction in early tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

THE EFFECT OF LIPIDS AND SERUM ALBUMIN ON BACTERIAL GROWTH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Airborne immunization against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

An apparatus for airborne infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

FURTHER EXPERIMENTS ON LONG-TERM CHEMOTHERAPY OF ADVANCED MURINE TUBERCULOSIS, WITH EMPHASIS ON INTERMITTENT REGIMES.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Late results of long-term, intermittent chemotherapy of advanced, murine tuberculosis: Limits of the murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Latest results of east African/British Medical Research Council short course chemotherapy studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Experimental models of tuberculosis: can we trust the mouse?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Ipr1 gene mediates innate immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Multigenic control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7 and its synergism with sst1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

ExperimentalMycobacterium tuberculosisInfection of Cynomolgus Macaques Closely Resembles the Various Manifestations of HumanM. tuberculosisInfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The use of the rabbit in experimental chemotherapy of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Pathogenesis of pulmonary Mycobacterium bovis infection: basic principles established by the rabbit model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Animal models of cavitation in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The American cotton rat: a novel model for pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Pathological and immunological profiles of rat tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Nude rat (F344/N-rnu) tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Macaque models of human infectious disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Lessons from experimental Mycobacterium tuberculosis infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Bactericidal Activity of Streptomycin, Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Alone and In Combination Against Mycobacterium Tuberculosis1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Replication dynamics of Mycobacterium tuberculosis in chronically infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

A replication clock for Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Metaplastic ossification in the cartilage of the bronchus of a patient with chronic multi-drug resistant tuberculosis: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Independent large scale duplications in multiple M. tuberculosis lineages overlapping the same genomic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Host-pathogen coevolution in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Genetic diversity of human isolates of Mycobacterium bovis assessed by spoligotyping and Variable Number Tandem Repeat genotyping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Variable host-pathogen compatibility in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

In Vivo Phenotypic Dominance in Mouse Mixed Infections withMycobacterium tuberculosisClinical Isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Combination of single nucleotide polymorphism and variable-number tandem repeats for genotyping a homogenous population of Mycobacterium tuberculosis Beijing strains in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Evaluation of standard chemotherapy in the guinea pig model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

TB day summit in upstate New York: Key issues to address

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Novel human in vitro system for evaluating antimycobacterial vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Identification of viable and non-viable Mycobacterium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Biomarkers for tuberculosis disease activity, cure, and relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

Translating animal research into clinical benefit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

The effect of tween 80 in vitro on the bacteriostatic activity of 20 compounds for Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

7 January 2021

Studies on the metabolism of Mycobacterium tuberculosis. IV. The effect of fatty acids on the growth of M. tuberculosis var. hominis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

7 January 2021

Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

7 January 2021

ANTAGONISM OF d -CYCLOSERINE INHIBITION OF MYCOBACTERIAL GROWTH BY d -ALANINE

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.07.003

7 January 2021

10.1016/J.TUBE.2012.07.003

Identifiers

DOI

1 reference

27 August 2017

1 reference